Journal
ONCOIMMUNOLOGY
Volume 4, Issue 9, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/2162402X.2014.985930
Keywords
breast cancer; TNBC; biomarker; tumor infiltrating lymphocytes
Categories
Funding
- NCATS NIH HHS [UL1 TR001073] Funding Source: Medline
- NCI NIH HHS [U10 CA180795, P30 CA016087] Funding Source: Medline
Ask authors/readers for more resources
Upon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS). 1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available